ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,220.36
-0.06%
Dow Jones
39,127.80
0.04%
Gold vs US Dollar
2,300.625
0.10%
Brent Oil
84.425
-0.05%
Bitcoin
60,697.00
-0.19%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Innate Pharma SA (IPHA)

  7. Innate Pharma SA (IPHA) News

Innate Pharma (IPHA)

Innate Pharma SA
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IPHA
DateTimeSourceHeadlineSymbolCompany
18/06/202406:00Business WireNouveau nombre d’actions et de droits de vote d’Innate Pharma au 10 juin 2024NASDAQ:IPHAInnate Pharma SA
18/06/202406:00Business WireNumber of Shares and Voting Rights of Innate Pharma as of June 10, 2024NASDAQ:IPHAInnate Pharma SA
17/06/202406:00Business WireInnate Pharma partage de nouveaux résultats concernant l’essai de Phase 1/2 mené par Sanofi évaluant le NK cell engager SAR443579/IPH6101 dans divers cancers du sangNASDAQ:IPHAInnate Pharma SA
17/06/202406:00Business WireInnate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 TrialNASDAQ:IPHAInnate Pharma SA
04/06/202411:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
04/06/202406:00Business WireInnate Pharma présente les résultats positifs de l’étude de Phase 2 TELLOMAK évaluant lacutamab dans le mycosis fongoïdeNASDAQ:IPHAInnate Pharma SA
04/06/202406:00Business WireInnate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis FungoidesNASDAQ:IPHAInnate Pharma SA
28/05/202411:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
28/05/202406:00Business WireInnate Pharma Announces Its Participation in Upcoming Investor ConferencesNASDAQ:IPHAInnate Pharma SA
28/05/202406:00Business WireInnate Pharma annonce sa participation à de prochaines conférences investisseursNASDAQ:IPHAInnate Pharma SA
24/05/202411:35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
24/05/202406:00Business WireInnate Pharma Highlights Abstracts Selected for ASCO 2024 Annual MeetingNASDAQ:IPHAInnate Pharma SA
24/05/202406:00Business WireInnate Pharma partage les abstracts sélectionnés pour le congres annuel de l’ASCO 2024NASDAQ:IPHAInnate Pharma SA
23/05/202421:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
23/05/202421:00Business WireOutcome of Innate Pharma’s 2024 Annual General MeetingNASDAQ:IPHAInnate Pharma SA
23/05/202421:00Business WireRésultats de l’Assemblée Générale mixte du 23 mai 2024NASDAQ:IPHAInnate Pharma SA
21/05/202406:00Business WireInnate Pharma: Clarification Regarding SAR443579 DesignationNASDAQ:IPHAInnate Pharma SA
21/05/202406:00Business WireInnate Pharma: Clarification concernant le statut de SAR443579NASDAQ:IPHAInnate Pharma SA
15/05/202411:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
15/05/202406:00Business WireInnate Pharma partage les abstracts sélectionnés pour le congrès 2024 de l’EHANASDAQ:IPHAInnate Pharma SA
15/05/202406:00Business WireInnate Pharma Highlights Abstracts Selected for EHA 2024 CongressNASDAQ:IPHAInnate Pharma SA
14/05/202406:00Business WireInnate Pharma Reports First Quarter 2024 Business Update and Financial ResultsNASDAQ:IPHAInnate Pharma SA
14/05/202406:00Business WireInnate Pharma fait le point sur ses activités et publie ses résultats financiers pour le premier trimestre 2024NASDAQ:IPHAInnate Pharma SA
07/05/202406:00Business WireInnate Pharma Announces Conference Call and Webcast for Q1 2024 Business UpdateNASDAQ:IPHAInnate Pharma SA
07/05/202406:00Business WireInnate Pharma organise une conférence téléphonique pour présenter ses résultats au premier trimestre 2024NASDAQ:IPHAInnate Pharma SA
15/04/202406:00Business WireInnate Pharma annonce la progression de l’essai clinique évaluant le NK Cell Engager SAR443579 / IPH6101 développé par Sanofi vers la Phase 2 dans divers cancers du sangNASDAQ:IPHAInnate Pharma SA
15/04/202406:00Business WireInnate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer PatientsNASDAQ:IPHAInnate Pharma SA
15/04/202406:00Business WireL’Assemblée Générale d’Innate Pharma aura lieu le 23 mai 2024NASDAQ:IPHAInnate Pharma SA
15/04/202406:00Business WireInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024NASDAQ:IPHAInnate Pharma SA
10/04/202406:00Business WireInnate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug ConjugateNASDAQ:IPHAInnate Pharma SA
 Showing the most relevant articles for your search:NASDAQ:IPHA

Your Recent History

LSE
SNG
Synairgen
LSE
IES
Invinity Energy Systems
LSE
LBE
Longboat Energy
LSE
GDR
Genedrive
LSE
ENET
Ethernity Networks
LSE
FIN
Finseta
LSE
PFC
Petrofac
LSE
RGL
Regional Reit
LSE
PCIP
Pci-pal
LSE
TIME
Time Finance
LSE
GOLD
LSE
PANR
Pantheon Resources
LSE
GKP
Gulf Keystone Petroleum
LSE
BGO
Bango
LSE
QBT
Quantum Blockchain Techn...
LSE
INSP
Inspirit Energy
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved